152 related articles for article (PubMed ID: 16778114)
1. Expression of tumor necrosis factor--related apoptosis-inducing ligand receptors 1 and 2 in melanoma.
McCarthy MM; DiVito KA; Sznol M; Kovacs D; Halaban R; Berger AJ; Flaherty KT; Camp RL; Lazova R; Rimm DL; Kluger HM
Clin Cancer Res; 2006 Jun; 12(12):3856-63. PubMed ID: 16778114
[TBL] [Abstract][Full Text] [Related]
2. Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer.
McCarthy MM; Sznol M; DiVito KA; Camp RL; Rimm DL; Kluger HM
Clin Cancer Res; 2005 Jul; 11(14):5188-94. PubMed ID: 16033835
[TBL] [Abstract][Full Text] [Related]
3. TRAIL-receptor expression is an independent prognostic factor for survival in patients with a primary glioblastoma multiforme.
Kuijlen JM; Mooij JJ; Platteel I; Hoving EW; van der Graaf WT; Span MM; Hollema H; den Dunnen WF
J Neurooncol; 2006 Jun; 78(2):161-71. PubMed ID: 16544055
[TBL] [Abstract][Full Text] [Related]
4. Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL- and CD95L-mediated apoptosis.
Geserick P; Drewniok C; Hupe M; Haas TL; Diessenbacher P; Sprick MR; Schön MP; Henkler F; Gollnick H; Walczak H; Leverkus M
Oncogene; 2008 May; 27(22):3211-20. PubMed ID: 18084329
[TBL] [Abstract][Full Text] [Related]
5. Efficient TRAIL-R1/DR4-mediated apoptosis in melanoma cells by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
Kurbanov BM; Geilen CC; Fecker LF; Orfanos CE; Eberle J
J Invest Dermatol; 2005 Nov; 125(5):1010-9. PubMed ID: 16297203
[TBL] [Abstract][Full Text] [Related]
6. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M
Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347
[TBL] [Abstract][Full Text] [Related]
7. Progression in melanoma is associated with decreased expression of death receptors for tumor necrosis factor-related apoptosis-inducing ligand.
Zhuang L; Lee CS; Scolyer RA; McCarthy SW; Zhang XD; Thompson JF; Screaton G; Hersey P
Hum Pathol; 2006 Oct; 37(10):1286-94. PubMed ID: 16949935
[TBL] [Abstract][Full Text] [Related]
8. Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin's lymphoma.
Lee SH; Shin MS; Kim HS; Lee HK; Park WS; Kim SY; Lee JH; Han SY; Park JY; Oh RR; Kang CS; Kim KM; Jang JJ; Nam SW; Lee JY; Yoo NJ
Oncogene; 2001 Jan; 20(3):399-403. PubMed ID: 11313970
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors in renal cell cancer.
Macher-Goeppinger S; Aulmann S; Tagscherer KE; Wagener N; Haferkamp A; Penzel R; Brauckhoff A; Hohenfellner M; Sykora J; Walczak H; Teh BT; Autschbach F; Herpel E; Schirmacher P; Roth W
Clin Cancer Res; 2009 Jan; 15(2):650-9. PubMed ID: 19147771
[TBL] [Abstract][Full Text] [Related]
10. Tunicamycin sensitizes human melanoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by up-regulation of TRAIL-R2 via the unfolded protein response.
Jiang CC; Chen LH; Gillespie S; Kiejda KA; Mhaidat N; Wang YF; Thorne R; Zhang XD; Hersey P
Cancer Res; 2007 Jun; 67(12):5880-8. PubMed ID: 17575157
[TBL] [Abstract][Full Text] [Related]
11. Rheumatoid arthritis synovial fluid macrophages express decreased tumor necrosis factor-related apoptosis-inducing ligand R2 and increased decoy receptor tumor necrosis factor-related apoptosis-inducing ligand R3.
Perlman H; Nguyen N; Liu H; Eslick J; Esser S; Walsh K; Moore TL; Pope RM
Arthritis Rheum; 2003 Nov; 48(11):3096-101. PubMed ID: 14613271
[TBL] [Abstract][Full Text] [Related]
12. The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization.
Kluger HM; McCarthy MM; Alvero AB; Sznol M; Ariyan S; Camp RL; Rimm DL; Mor G
J Transl Med; 2007 Jan; 5():6. PubMed ID: 17257402
[TBL] [Abstract][Full Text] [Related]
13. Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers.
Shin MS; Kim HS; Lee SH; Park WS; Kim SY; Park JY; Lee JH; Lee SK; Lee SN; Jung SS; Han JY; Kim H; Lee JY; Yoo NJ
Cancer Res; 2001 Jul; 61(13):4942-6. PubMed ID: 11431320
[TBL] [Abstract][Full Text] [Related]
14. Expression of tumor necrosis factor alpha, TNF-related apoptosis-inducing ligand, and their associated molecules in ameloblastomas.
Kumamoto H; Ooya K
J Oral Pathol Med; 2005 May; 34(5):287-94. PubMed ID: 15817072
[TBL] [Abstract][Full Text] [Related]
15. Absence of gene mutation in TRAIL receptor 1 (TRAIL-R1) and TRAIL receptor 2 (TRAIL-R2) in chronic myelogenous leukemia and myelodysplastic syndrome, and analysis of mRNA Expressions of TRAIL and TRAIL-related genes in chronic myelogenous leukemia.
Liu LG; Tanaka H; Ito K; Ito T; Sultana TA; Kyo T; Kimura A
Acta Haematol; 2005; 113(2):113-23. PubMed ID: 15802890
[TBL] [Abstract][Full Text] [Related]
16. TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies.
MacFarlane M; Kohlhaas SL; Sutcliffe MJ; Dyer MJ; Cohen GM
Cancer Res; 2005 Dec; 65(24):11265-70. PubMed ID: 16357130
[TBL] [Abstract][Full Text] [Related]
17. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling.
Chen X; Kandasamy K; Srivastava RK
Cancer Res; 2003 Mar; 63(5):1059-66. PubMed ID: 12615723
[TBL] [Abstract][Full Text] [Related]
18. The melanoma-associated antigen MAGE-D2 suppresses TRAIL receptor 2 and protects against TRAIL-induced apoptosis in human melanoma cells.
Tseng HY; Chen LH; Ye Y; Tay KH; Jiang CC; Guo ST; Jin L; Hersey P; Zhang XD
Carcinogenesis; 2012 Oct; 33(10):1871-81. PubMed ID: 22791814
[TBL] [Abstract][Full Text] [Related]
19. A study of TRAIL receptors in squamous cell carcinoma of the head and neck.
Teng MS; Brandwein-Gensler MS; Teixeira MS; Martignetti JA; Duffey DC
Arch Otolaryngol Head Neck Surg; 2005 May; 131(5):407-12. PubMed ID: 15897419
[TBL] [Abstract][Full Text] [Related]
20. Functional expression of TRAIL receptors TRAIL-R1 and TRAIL-R2 in esophageal adenocarcinoma.
Younes M; Georgakis GV; Rahmani M; Beer D; Younes A
Eur J Cancer; 2006 Mar; 42(4):542-7. PubMed ID: 16426839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
